摘要
目的：分析与探讨采用宁泌泰胶囊联合盐酸坦洛新缓释胶囊治疗ⅢB型前列腺炎患者的临床疗效,并研究其对前列腺液IL-10、TNF-α、PGE-2的影响。方法：94例ⅢB型前列腺炎患者采用数字表法,根据用药治疗方案不同,分成两组,每组47例。对照组给予盐酸坦洛新缓释胶囊治疗,观察组给予宁泌泰胶囊联合盐酸坦洛新缓释胶囊治疗。观察两组前列腺炎症状评分、前列腺液IL-10、TNF-α、PGE-2变化、不良反应、临床治疗效果、尿动力学以及白细胞计数变化情况。结果：观察组治疗后排尿症状评分（3.23±0.21）分、疼痛不适症状评分（4.89±0.66）分、生活质量评分（3.67±0.97）分、临床总有效率（93.62%）、IL-10（3.24±0.95）ng/L、TNF-α（41.24±7.23）pg/mL、PGE-2（39.79±5.66）pg/mL、MRF（29.81±2.11）mL/s、RVU（6.19±1.47）mL、白细胞计数（12.91±2.12）个/HP等均明显优于对照组排尿症状评分（4.89±0.66）分、疼痛不适症状评分（8.72±1.28）分、生活质量评分（5.42±1.11）分、临床总有效率（76.60%）、IL-10（3.91±1.07）ng/L、TNF-α（55.62±7.04）pg/mL、PGE-2（52.87±5.43）pg/mL、MRF（15.65±2.39）mL/s、RVU（11.24±2.26）mL、白细胞计数（19.68±2.09）个/HP,差异有统计学意义（P〈0.05）。两组不良反应发生情况比较无差异（P〉0.05）。结论：采用宁泌泰胶囊及盐酸坦洛新缓释胶囊联合治疗ⅢB型前列腺炎患者,能够显著改善其临床症状及尿动力学相关指标,促进患者疾病相关炎症因子水平及免疫功能情况恢复,能够明显提升临床疗效,同时安全性较好,有助于患者预后。
Objective：To analyze and explore the clinical efficacy of Ningmitai Capsule combined with Tamsulosin Hydrochloride Sustained Release Capsules in the treatment of type Ⅲ B prostatitis and study its effect on IL-10,PGE-2 and TNF-α in prostatic fluid. Methods：94 patients with type Ⅲ B prostatitis were studied by digital table method. According to the different treatment schemes, the patients were divided into two groups, 47 cases in each group. The control group was treated with Tamsulosin Hydrochloride Sustained Release Capsules, and the observation group was treated with Ningmitai Capsule combined with Tamsulosin Hydrochloride Sustained Release Capsules. Inflammatory symptoms score, adverse reaction, prostatic IL-10, TNF-α and PGE-2 changes, clinical effects and urodynamic changes in white blood cell count were compared.Results：After treatment,the observation group＇s voiding symptom score（3.23±0.21）, pain symptoms score（4.89±0.66）, quality of life score（3.67±0.97）, the total clinical efficiency（93.62%）, IL-10（3.24±0.95）ng/L, TNF-α（41.24±7.23）pg/mL, PGE-2（39.79±5.66）pg/mL, MRF（29.81±2.11）mL/s, RVU（6.19±1.47）mL and white blood cell count（12.91±2.12）/HP were significantly better than the control group＇s voiding symptom score（4.89±0.66）, pain symptoms score（8.72±1.28）, quality of life score（5.42±1.11）, the total clinical efficiency（76.60%）, IL-10（3.91±1.07）ng/L, TNF-α（55.62±7.04） pg/mL, PGE-2（52.87±5.43）pg/mL, MRF（15.65±2.39）mL/s, RVU（11.24±2.26） mL and white blood cell count（19.68±2.09）/HP, and the difference was statistically significant（P〈0.05）. There was no difference in the incidence of adverse reactions between the two groups（P〈0.05）. Conclusion：Ningmitai Capsule and Tamsulosin Hydrochloride Sustained Release Capsules were used in the treatment of type Ⅲ B prostatitis. It can significantly improve the clinical symptoms and urodynamic indexes, promote the recovery of disease related inflammatory factors and immune function. It can improve the clinical efficacy, and the safety is good, and it can help the patients＇ prognosis.
作者
杨庆
胡洋
吴海啸
张恒
YANG Qing;HU Yang;WU Haixiao;ZHANG Heng(Department of Urology,Jinhua Center Hospital,Jinhua 321000,Zhejiang,China)
出处
《中华中医药学刊》
CAS
北大核心
2018年第11期2750-2753,共4页
Chinese Archives of Traditional Chinese Medicine
基金
浙江省中医药科技计划项目(2013AZ221)
